Építés alatt – nem éles oldal
Belépés
Fut, nem toborozFázis nélkül

Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation

A legfontosabb adatok

Ki végzi
University of Luebeck
Hol
Németország1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Fut, nem toboroz
Résztvevők
114 fő vett részt
Kezdés
2022. márc. 17.
Várható befejezés
2030. jún. 30.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • autologous PRP (platelet rich plasma)
  • Saline solution (NaCL) Injection
A regiszteradat frissítve
2025. június 4.

Ki vehet részt

Életkor
18 év – 42 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 26 feltétel megnézéseKevesebb

Ki vehet részt

  • Serum AMH < 0.5 ng/ml (at screening visit and in the absence of OC or sex-steroid intake)
  • Antral follicular count (AFC) in both ovaries ≤ 5 (at screening visit and in the absence of OC or sex-steroid intake)
  • Spontaneous cycle, menstrual cycle length 21-35 days
  • Body mass index (BMI) ≥18 kg/m2 and ≤38 kg/m2
  • Both ovaries must be visible by transvaginal ultrasound examination
  • Both ovaries must be judged accessible by transvaginal puncture
  • Indication for IVF or ICSI treatment
  • Willingness to participate and provide written consent prior to initiation of any study-related procedures
  • The subject and male partner must agree to participate in the infant follow-up if she becomes pregnant
  • The subject must be able to communicate well with the investigator and research staff and to comply with the requirements of the study protocol

Ki nem vehet részt

  • ≥ four cumulus-oocyte-complexes (COCs) retrieved in a previous IVF cycles with a conventional stimulation protocol (within 6 months before enrollment)
  • Oral contraceptive or sex steroid intake within 1 month prior to enrollment
  • Contraindication for transvaginal ovarian puncture (such as previous major lower abdominal surgery and known severe pelvic adhesion)
  • Relevant autoimmune disease
  • History of malignancy and systemic chemotherapy or pelvic radiation
  • Relevant endocrine disorders such as hypothalamic-pituitary disorder or thyroid dysfunction (except substituted Hashimoto's thyroiditis or latent hypothyroidism)
  • Relevant thrombophilic disorder
  • Serum value of FSH ≥25 IU/l (within 12 months measured in the absence of OC or hormone replacement intake)
  • Thrombocytopenia defined as < 100.000 platelets/µl at screening
  • Presence of structural or numerical chromosomal abnormality in cytogenetic analysis
  • Severe endometriosis (stage III-IV)
  • Ovaries located outside the inner pelvis
  • Presence of unilateral or bilateral hydrosalpinx
  • Contraindication for pregnancy
  • Uterine malformations or pathologies (such as sub mucosal fibroid(s), endometrial hyperplasia, endometrial fluid accumulation, or endometrial adhesions)
  • Mental disability or any other lack of fitness, in the investigator's opinion, to preclude subjects in or to complete the study

Ennek a vizsgálatnak nincs helyszíne itt: Egyesült Államok.

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary objective is to investigate the efficacy, defined as an increase in oocyte numbers upon ovarian stimulation, and safety of a single intra-ovarian PRP injection vs. saline solution (NaCl) injection (Placebo) transvaginally or laparoscopically for follicular activation in patients with child wish and with low ovarian reserve/expected poor ovarian response planning to undergo IVF or ICSI using own eggs. Pain score as numerical rating score and validated quality of life questionnaire will be requested after the procedure. Longterm follow-up of all participants will be performed 1, 2 and 5 years after end of study.

A vizsgálat 2 csoportja

  • Autologous intra-ovarian PRP injectionA vizsgált kezelés

    Study group, treated with autologous intra-ovarian PRP injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention

    Kezelés: autologous PRP (platelet rich plasma)

  • intra-ovarian saline solution (NaCL) injectionPlacebo, összehasonlításként

    Control group, treated with intra-ovarian NaCl injection and undergoing a subsequent fresh ET-IVF/ICSI cycle in the third cycle after intervention

    Kezelés: Saline solution (NaCL) Injection

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
The Efficacy and Safety of Intra-ovarian PRP Injection Within a Prospective, Single-blinded, Placebo-controlled, Randomized, Clinical Superiority Trial in Subjects With Low Ovarian Reserve/Expected Poor Ovarian Response
A regiszteradat frissítve
2025. június 4.